Jacobs Levy Equity Management’s Aldeyra Therapeutics ALDX Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.38M	Sell	646,840 -149,976	-19%	-$258K	0.01%	665
2026 Q1	$1.35M	Sell	796,816 -171,935	-18%	-$753K	0.01%	660
2025 Q4	$5.02M	Buy	968,751 +21,200	+2%	+$109K	0.02%	410
2025 Q3	$4.95M	Buy	947,551 +313,395	+49%	+$1.63M	0.02%	428
2025 Q2	$2.43M	Buy	634,156 +596,172	+1,570%	+$1.54M	0.01%	583
2025 Q1	$218K	Buy	+37,984	New	+$225K	﹤0.01%	1020
2024 Q4	–	Sell	-476,949	Closed	-$2.57M	–	930
2024 Q3	$2.57M	Buy	476,949 +295,864	+163%	+$1.41M	0.01%	558
2024 Q2	$599K	Buy	181,085 +2,166	+1%	+$8.48K	﹤0.01%	816
2024 Q1	$585K	Buy	+178,919	New	+$589K	﹤0.01%	803
2023 Q1	–	Sell	-21,374	Closed	-$149K	–	950
2022 Q4	$149K	Sell	21,374 -260,462	-92%	-$1.49M	﹤0.01%	916
2022 Q3	$1.5M	Buy	281,836 +47,166	+20%	+$283K	0.01%	615
2022 Q2	$936K	Buy	+234,670	New	+$807K	0.01%	767
2021 Q3	–	Sell	-43,069	Closed	-$488K	–	1027
2021 Q2	$488K	Hold	43,069	–	–	﹤0.01%	864
2021 Q1	$512K	Sell	43,069 -254,763	-86%	-$2.93M	﹤0.01%	860
2020 Q4	$2.04M	Sell	297,832 -8,002	-3%	-$56.2K	0.02%	582
2020 Q3	$2.27M	Buy	305,834 +795	+0.3%	+$5.13K	0.02%	498
2020 Q2	$1.27M	Buy	305,039 +260,076	+578%	+$950K	0.01%	620
2020 Q1	$111K	Buy	44,963 +17,131	+62%	+$77K	﹤0.01%	953
2019 Q4	$162K	Buy	+27,832	New	+$161K	﹤0.01%	954

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jacobs Levy Equity Management's ALDX Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Aldeyra Therapeutics (ALDX) stake by 19% in Q2 2026, selling an estimated $258K and leaving 646,840 shares worth $1.38M. The position accounts for 0.01% of the portfolio, ranked #665.

Jacobs Levy Equity Management first reported a position in ALDX in Q4 2019 and has held it in 19 quarters since. The position peaked at $5.02M in Q4 2025. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Jacobs Levy Equity Management held 646,840 shares of Aldeyra Therapeutics worth $1.38M as of Q2 2026.
Jacobs Levy Equity Management sold 149,976 Aldeyra Therapeutics shares in Q2 2026, an estimated $258K.
Aldeyra Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #665 holding.
Jacobs Levy Equity Management first reported a position in Aldeyra Therapeutics in Q4 2019 and has held it in 19 quarters since.
Jacobs Levy Equity Management's Aldeyra Therapeutics position peaked at $5.02M in Q4 2025.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.